{"id":768644,"date":"2025-10-14T14:13:01","date_gmt":"2025-10-14T14:13:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=768644"},"modified":"2025-10-14T14:13:01","modified_gmt":"2025-10-14T14:13:01","slug":"veterinary-vaccines-market-to-reach-usd-1333-billion-by-2029","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/veterinary-vaccines-market-to-reach-usd-1333-billion-by-2029_768644.html","title":{"rendered":"Veterinary Vaccines Market to Reach USD 13.33 Billion by 2029"},"content":{"rendered":"
\n
\"Veterinary<\/a><\/div>\n
\n
Asia Pacific was the fastest regional market for veterinary vaccines. Due to several factors, including a rapidly expanding livestock industry, increasing animal disease outbreaks, growing demand for animal-based products, and rising awareness about animal health, the market is significantly growing in this region.<\/div>\n<\/div>\n<\/div>\n
Some of the prominent players operating in the market include The prominent players in the veterinary vaccines market include Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US)<\/div>\n

The global Veterinary Vaccines Market<\/a><\/strong>, valued at USD 8.93 billion in 2023<\/strong>, is projected to grow at a CAGR of 6.1%<\/strong>, reaching USD 9.39 billion in 2024<\/strong> and USD 13.33 billion by 2029<\/strong>, according to MarketsandMarkets™.<\/p>\n

Market growth is driven by the rising companion animal population<\/strong>, increasing pet ownership<\/strong>, growing prevalence of zoonotic diseases<\/strong>, and government initiatives to improve animal health<\/strong>. However, high vaccine development and production costs<\/strong> remain a key challenge, potentially restraining market expansion.<\/p>\n

Successfully navigating these opportunities and constraints will be crucial for advancing innovation and adoption in veterinary vaccine solutions.<\/p>\n

Market Segmentation Insights<\/strong><\/p>\n

By Type:<\/strong> The market is segmented into porcine<\/strong>, poultry<\/strong>, livestock<\/strong>, aquaculture<\/strong>, companion animal<\/strong>, and other animal vaccines<\/strong>. In 2023, the livestock vaccines<\/strong> segment accounted for the largest share. The rising global demand for meat and dairy products<\/strong>, coupled with the need to maintain herd health and prevent disease outbreaks<\/strong>, is driving this segment’s growth.<\/p>\n

By Disease:<\/strong> Livestock disease vaccines held the largest share in 2021, supported by growing meat and milk consumption<\/strong>, dairy industry expansion<\/strong>, and awareness about disease prevention<\/strong>. Effective livestock vaccination plays a vital role in ensuring food security<\/strong>, boosting productivity<\/strong>, and reducing zoonotic risks<\/strong>.<\/p>\n

By Technology:<\/strong> The market is segmented into live attenuated<\/strong>, inactivated<\/strong>, toxoid<\/strong>, recombinant<\/strong>, and other vaccines<\/strong> (including subunit, RNA particle, and immune complex technologies). In 2023, live attenuated vaccines<\/strong> led the market due to their high efficacy<\/strong>, cost-effectiveness<\/strong>, and long-term immunity<\/strong>. These vaccines are preferred for managing widespread livestock diseases, particularly in regions with intensive animal farming and growing trade activities.<\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=1233<\/a><\/strong><\/p>\n

Regional Insights<\/strong><\/p>\n

The global market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa<\/strong>. In 2023, the Asia Pacific<\/strong> emerged as the fastest-growing regional market<\/strong>, driven by:<\/p>\n